Not sure that its all over for Biotron, just difficulty finding a market in time.
BLT owns the IP for ddRNAi. They have a platform not a drug.
BLT is only just beginning to prove itself as the superior gene silencing technology. Their HCV trial, if successful will carve a niche out in the market through effectivenes and price. It is fair to say that the DAAs from Gilead and Abbvie have the jump in the HCV space. Benitec are not a one trick pony and do not compare with Biotron in any way.
I am not here to push them but to keep interested people informed and hopefully learn more myself while I am at it.
johnson & johnson, page-16
-
- There are more pages in this discussion • 21 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BIT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.0¢ |
Change
-0.003(9.09%) |
Mkt cap ! $27.06M | |||
| Open | High | Low | Value | Volume |
| 3.3¢ | 3.4¢ | 3.0¢ | $32.26K | 1.016M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 720804 | 3.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.1¢ | 30000 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2024 (20 minute delay) ? |
| BIT (ASX) Chart |